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Pathogen adaptation has been proposed to contrib-
ute to the resurgence of pertussis. A striking recent 
example is the emergence of isolates deficient in 
the vaccine component pertactin (Prn). This study 
explores the emergence of such Prn-deficient isolates 
in six European countries. During 2007 to 2009, 0/83 
isolates from the Netherlands, 0/18 from the United 
Kingdom, 0/17 Finland, 0/23 Denmark, 4/99 Sweden 
and 5/20 from Norway of the isolates collected were 
Prn-deficient. In the Netherlands and Sweden, respec-
tively 4/146 and 1/8 were observed in a later period 
(2010–12). The Prn-deficient isolates were geneti-
cally diverse and different mutations were found to 
inactivate the prn gene. These are indications that 
Prn-deficiency is subject to positive selective pres-
sure. We hypothesise that the switch from whole cell 
to acellular pertussis vaccines has affected the bal-
ance between ‘costs and benefits’ of Prn production 
by Bordetella pertussis to the extent that isolates that 
do not produce Prn are able to expand. The absence of 
Prn-deficient isolates in some countries may point to 
ways to prevent or delay the spread of Prn-deficient 
strains. In order to substantiate this hypothesis, 
trends in the European B. pertussis population should 
be monitored continuously. 
Introduction
Introduction of whole cell pertussis vaccines (WCVs) 50 
to 60 years ago has greatly reduced the pertussis bur-
den worldwide [1]. However, despite a vaccine coverage 
between 80% and 96%, pertussis has resurged in many 
countries [2,3]. In particular, in the last few years, high 
incidences have been observed in the Netherlands, the 
United Kingdom (UK) and the United States (US) [4-6]. 
Several causes have been proposed for the resurgence 
of pertussis, including waning immunity and pathogen 
adaptation [7].
In the 1990s, less-reactive acellular pertussis vaccines 
(ACVs) replaced WCVs. ACVs contain between one and 
five pertussis proteins: (i) pertussis toxin (Ptx); (ii) 
pertactin (Prn); (iii) serotype 2 fimbriae (Fim2); (iv) 
serotype 3 fimbriae (Fim3); and (v) filamentous hae-
magglutinin (FHA). All ACVs contain Ptx. The effec-
tiveness of the different available WCVs was highly 
variable [8], which complicates evaluation of the pro-
tection that ACVs induce compared with that of WCVs. 
However, recently, several studies have indicated that 
the immunity induced by ACVs is less long-lasting com-
pared with effective WCVs, resulting in a higher pertus-
sis burden, particularly in children aged 6 to 10 years 
[9-12].
The effect of waning immunity may have been aggra-
vated by pathogen adaptation [7], which is reflected in 
large shifts in Bordetella pertussis populations [13-15]. 
Observed adaptations include antigenic divergence 
between circulating strains and vaccine strains, and 
the emergence of strains with a novel promoter for Ptx 
(ptxP3) [16]. In addition, most recently, strains have 
emerged that do not express Prn, hereafter named 
Prn-deficient strains [17-22]. Isolates with the ptxP3 
promoter increased in frequency in the 1980s and at 
present they predominate in many countries, reflect-
ing a global selective sweep [6,13,16,23-26]. The ptxP3 
isolates produce higher amounts of Ptx in vitro (1.6-
fold increase), when compared with the ptxP1 isolates 
they replaced [16]. It has been suggested that this may 
result in a more effective suppression of host immunity 
[16]. In agreement with this, ptxP3 isolates reach higher 
bacterial densities than ptxP1 isolates in mice [27]. Prn-
deficient isolates emerged around 2000 and have been 
found in Finland, France, Japan and the US [18-20,22]. 
In addition, less frequently, isolates were found that 
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do not produce FHA or Ptx. Hegerle et al. reported one 
isolate lacking both Prn and FHA, and one isolate lack-
ing Ptx [17,19]. Bouchez et al. have suggested that the 
emergence of such isolates is related to the introduc-
tion of ACVs [17,28]. Prn-deficient isolates have been 
isolated from pertussis patients and seemed to be as 
virulent as isolates expressing Prn in infants less than 
six months of age as well as in a mouse model [17,29]. 
A better understanding of the epidemiology and viru-
lence of Prn-deficient isolates is crucial for the devel-
opment of next-generation pertussis vaccines.
In this study, we investigated the emergence and 
spread of Prn-deficient isolates in Europe. To do so, 
we combine single nucleotide polymorphism (SNP) typ-
ing, antigen expression analysis and DNA sequencing 
with epidemiological data. The diversity of vaccination 
programmes in Europe (Table 1) offers a unique oppor-
tunity to study the effect, if any, of vaccination policy 
on the emergence of Prn-deficient strains. Ultimately, 
we aim to define conditions that could prevent or ham-
per the emergence of vaccine-adapted strains. This 
study provides a baseline for future European studies 
in which the occurrence and spread of Prn-deficient 
strains will be investigated.
Methods
Analysis of Bordetella pertussis isolates
Six countries provided a total of 665 strains isolated 
from nasopharyngeal swabs from confirmed pertus-
sis patients for this study: Denmark (n=43), Finland 
(n=56), Netherlands (n=311), Norway (n=20), Sweden 
(n=197) and the UK (for the purposes of this article, 
the UK is considered as one country) (n=38) (Table 
2). These countries were selected as they are mem-
bers of European research programme for improved 
pertussis strain characterisation and surveillance 
(EUPERTSTRAIN) network and were able to contribute 
strains. The strains were isolated during 1996 to 2012. 
In the countries studied, primary immunisation with 
ACVs was introduced between 1996 and 2005 (Table 
1). Furthermore, in these countries, different ACVs and 
different vaccine strategies were used and the vac-
cine coverage varied (Table 1). Strains were grouped 
into three periods, 1996–2006, 2007–09 and 2010–12 
(periods I, II and III, respectively). Bacteria were cul-
tured on Bordet Gengou agar plates supplemented with 
15% sheep blood and incubated at 35 °C for 3 to 4 days.
PCR and DNA sequencing
DNA isolation was performed using the GenElute 
Bacterial Genomic DNA Kit (Sigma-Aldrich, Zwijndrecht, 
Table 1
Year of introduction, vaccine composition and vaccination coverage of acellular pertussis vaccines in six European countries
Country Year of ACV introductiona,b
Primary series
Age <13 months
Childhood booster
Age 13 months–10 years
Adolescent booster
Age 11–20 years Reference
ACVc Vaccination coverage ACV
c Vaccination 
coverage ACV
c Vaccination 
coverage
Denmark
1997 1 >90% – – – –
[39]
2003 – – 1 >80% – –
Finland
2003 – – 3 – – –
[20]
2005 2 or 3 >99% 2 or 3 – 3 –
Netherlands
2001 – – 3 or 5 >95% – –
[40]
2005 3 or 5 >95% – – – –
Norway
1998 3 >90% – – – –
[41]
2006 – – 2 90% – –
Sweden
1996 1, 2 or 3 >98% – – – –
[40,42]
2007 – – 2 or 3 90% – –
United Kingdomb,d
2000 3 >90% – – – –
[43]Oct 2001 – – 3 or 5 – – –
2004 5 – 3 or 5 – – –
ACV: acellular pertussis vaccine; FHA: filamentous haemagglutinin;  Fim2: serotype 2 fimbriae; Fim3: serotype 3 fimbriae; Prn: pertactin; Ptx: 
pertussis toxin.
Dashes are used where data are not applicable.
a  The year in which ACVs were introduced as the primary series and as booster. 
b  In the United Kingdom, an ACV3 was used temporarily for the primary series until 2001. Thereafter, the whole cell pertussis vaccines was 
used again for the primary series, with addition of an ACV3 or ACV5 childhood booster in October 2001. Subsequently, in 2004 the ACV5 
was introduced permanently for the primary series.
c  Vaccine compositions are shown. ACV1: Ptx monocomponent; ACV2: Ptx, FHA; ACV3: Ptx, FHA, Prn; ACV5: Ptx, FHA, Prn, Fim2, Fim3.
d  For the purposes of this article, the United Kingdom is considered as one country.
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the Netherlands), following the manufacturer’s instruc-
tions for Gram-negative bacteria. For multi-antigen 
sequence typing (MAST), the pertussis toxin promoter 
(ptxP), regions 1 and 2 of the pertactin gene (prn), the 
genes for serotype 2 fimbriae (fim2) and serotype 3 
fimbriae (fim3) were sequenced in order to determine 
polymorphisms [16,30].
To determine the location and size of the mutation 
causing non-expression of Prn, four sets of primers 
were selected for PCR amplification of the prn gene 
(Table 3). Prn PCR products were visualised and sized 
by capillary electrophoresis on a QIAxcel instrument 
(Qiagen Benelux), using the QIAxcel high-resolution 
kit, QX DNA size marker 250–8,000 base pairs (bp) 
and QX alignment markers 15/8,000 bp. Each type of 
mutation was verified in at least one isolate by Sanger 
sequencing using an ABI 3700 DNA sequencer (Perkin-
Elmer Applied Biosystems).
Identification of vaccine antigen-deficient 
isolates
A microsphere-based Multiplex Immunoassay 
(Luminex, Austin, TX, US) [31] was developed to meas-
ure the expression of Ptx and Prn. Isogenic ptx (B0085) 
and prn (B1686) knockout strains were used as nega-
tive controls [32,33]. Analyses of these negative con-
trols resulted in values <5 ng/ml. Therefore, isolates 
with antigen concentrations <5 ng/ml were considered 
deficient isolates. All deficient isolates were tested 
at least twice, starting from independent cultures. In 
addition, Prn deficiency was verified with an immunob-
lot using the monoclonal antibody Prn Ab 62, E4D7 [34] 
(Figure 1).
Single nucleotide polymorphism typing and 
clustering analysis
SNP typing was used to establish genetic relationships 
between B. pertussis isolates [35,36]. A total of 113 
SNPs that are useful for discriminating between isolates 
were selected after comparing whole genome data of a 
selection of 74 worldwide isolates (data not shown). In 
order to study the origin and spread of European Prn-
deficient isolates, SNP typing was performed on 261 
isolates from all six countries using the Sequenom 
technology (Sequenom, San Diego, CA, US) [35]. At 
least 40 randomly selected strains (using the function 
RAND in Microsoft Excel) per country were typed, if 
available. A tree was constructed in Bionumerics 6•6 
(Applied Maths, Sint-Martens-Latem, Belgium), treat-
ing the SNPs as character data and using the neighbor-
joining algorithm. The vaccine strains B0006 (from the 
Netherlands, 1950, ptxP2), B0499 (ACV strain 10-536, 
1951, ptxP2) and B0005 (from the Netherlands, 1950, 
ptxP1) were included as outgroups.
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Results
Frequency of pertactin-deficient isolates in six 
European countries
Expression of Prn was assessed by a multiplex 
Immunoassay assay and immunoblotting (Figure 1) for 
576 of the 665 strains from the six countries, of which 
14 (2.4%) were shown to be Prn deficient (Tables 2 
and 4). All 576 strains tested positive for Ptx produc-
tion. For period I (1996–2006), only strains from the 
Netherlands (n=82) and Sweden (n=80) were available 
for this analysis. One Prn-deficient isolate from Finland 
was obtained in period I: this isolate was not included 
in the Prn-deficiency frequency analysis because no 
other Finnish isolates were analysed for Prn expression 
in that period. For period II (2007–09), between 17 and 
99 strains from each of the six countries were analysed 
for Prn expression. Prn-deficient strains were observed 
in Norway (5/20 strains) and Sweden (4/99), but not in 
Denmark (0/23), Finland (0/17), the Netherlands (0/83) 
or the UK (0/18). As for period I, for period III (2010–12) 
only strains from the Netherlands (n=146) and Sweden 
(n=8) were available for this analysis. In that period, 
4/146 Dutch strains and 1/8 Swedish strains were found 
to be Prn deficient. Thus, Prn-deficient isolates in the 
frequency analysis were detected in periods II and III. 
All isolates produced Ptx. The vaccination status of 14 
of the 15 patients from whom the Prn-deficient isolates 
were recovered was unknown (Table 4). Therefore, we 
cannot relate the infection with a Prn-deficient strain 
to the degree of immunisation.
Mutations causing non-expression of pertactin
Previous studies observed five types of mutations that 
inactivate the prn gene: inversion, deletion of (part of) 
the gene, insertion of IS481 into prn, insertion of a sin-
gle nucleotide resulting in a frameshift mutation, or a 
SNP resulting in the introduction of a stop codon [17-
22] (Figure 2, Table 5). We used PCR and sequencing of 
the prn gene to determine the cause of non-expression 
of the Prn-deficient isolates we analysed (Table 4). 
PCR fragment analysis showed that three Prn-deficient 
isolates (B3545, B3748, B3865) had an insertion of 
approximately 1 kilobase pair (kb) proximal to region 
2 (Figure 3). We assumed this is the result of an inser-
tion of IS481 into this region and no further sequencing 
analysis was performed on these isolates. Sequence 
data of the remaining 12 Prn-deficient isolates showed 
that in two isolates, the promoter region was inverted 
as described by Pawloski et al. [22]. Another three iso-
lates (B3582, B3640, B3891) had an IS element inserted 
proximal to one of the two repeat regions of the prn 
gene, designated region 2 (Figure 2). This mutation 
has also been found previously in French Prn-deficient 
isolates [17]. Sequence data of a sixth isolate (B3771), 
which originated from Finland in period I, contained a 
deletion of 49 bases in the signal sequence. This iso-
late was not included in the Prn-deficiency frequency 
analysis because no other Finnish isolates were ana-
lysed for Prn expression in period I. The seventh iso-
late, B3876 from The Netherlands, contained a SNP at 
position 223 that introduces a premature stop codon 
in the prn2 gene. An eighth isolate (B3658), originat-
ing from Norway, also contained a SNP that introduces 
a premature stop codon in prn2, but at position 1,273. 
Sequencing of the prn gene around position 1,273 
showed that the other four Norwegian Prn-deficient 
isolates also harboured this SNP.
Phylogenetic relationships of European 
pertactin-deficient Bordetella pertussis isolates
Typing of 261 isolates from the six different European 
countries using 113 SNPs allowed us to distinguish 20 
STs.
Phylogenetic analysis revealed a closely related 
European B. pertussis population (Figure 4). The tree 
topology showed two distinct clades containing ptxP1 
and ptxP3 isolates. In addition, a fim3.1 and a fim3.2 
cluster could be observed within the ptxP3 clade 
(Figure 4).
The 12 European Prn-deficient isolates included in the 
phylogenetic analyses were found in four different 
STs: ST13, ST14, ST17 and ST19 (Figure 4). These STs 
were among the predominant types and contained 70% 
(184/264) of the isolates analysed.
Table 3
Primers used for the characterisation of mutations leading to non-expression of pertactin in Bordetella pertussis isolates in 
six European countries, 1996–2012
PCR Primer name Primer sequence  (5’ to 3’) Positiona Reference
1
prn-SPF1 TCC CTG TTC CAT CGC GGT G 1098036–1098054
[44]
prn-SPR1 CCT GAG CCT GGA GAC TGG 1100878–1100895
2
prn-BF AGC TGG GCG GTT CAA GGT 1099489–1099506
[45]
prn-BR CGG AT T CAG GCG CAA CTC 1100006–1100024
3
prn-D1F CAT GAA ATC CGC CAT CCG CT 1095775–1095794
[this work]
prn-D1R ACT GGC CCC CAA CAC AGA CA 1098750–1098769
4
prn-D2F TAC TTT TGC TGC GCC CAT T 1098015–1098033
[this work]
prn-D2R CTT GAT GGT GGT TCC GCT G 1098283–1098301
F: forward primer; R: reverse primer.
a Position of the primer, relative to the origin of replication of reference strain Tohama (National Center for Biotechnology Information (NCBI) 
reference sequence NC_002929).
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All Prn-deficient isolates analysed in this study were 
found in the ptxP3 clade but were associated with 
both fim3.1 and fim3.2 alleles. ST14 contains two types 
of prn mutations (Table 4). In contrast, the five Prn-
deficient isolates that belong to ST13 all harboured the 
same mutation in prn: a SNP resulting in premature 
translational termination of prn. All five isolates were 
from Norway. The prn mutation, in which IS481 was 
inserted proximal to region 2, was found in three STs 
that were dispersed across the ptxP3 clade. This muta-
tion was associated with both the fim3.1 and fim3.2 
alleles. Thus, identical mutations were observed in dif-
ferent STs, while within a single ST, different mutations 
were found.
Discussion
The diversity in immunisation programmes in Europe 
offers an opportunity to explore the effect of vaccina-
tion strategies on adaptation of B. pertussis in popula-
tions with a vaccine coverage between 80% and 96%. 
In this study, the overall mean of Prn-deficient strains 
from six European countries isolated between 2007 
and 2012 was 3.4% (14/414 isolates). Bouchez et al. 
suggested that the emergence of French Prn-deficient 
isolates was driven by the switch from WCVs to ACVs 
[17]. Indeed, Prn-deficient isolates were rarely found 
before the introduction of ACVs, when WCVs were used 
[37]. Compared with the mean of Prn-deficient strains 
found in the six countries studied here (3.4%), higher 
percentages of Prn-deficient isolates were observed 
in France (13% in 2011), Japan (32% in 2005–09) and 
the US (53% in 2012) [18,19,22]. In Japan, ACVs were 
introduced in 1981 [18], and in the US, the first ACV 
was marketed in 1991. Thus, these countries have a 
longer history of ACV immunisation compared with the 
six countries included in this study, where ACVs vac-
cines for the primary series were introduced between 
1996 and 2005 (Table 1). Interestingly, the early Prn-
deficient strains found in this study were mainly from 
Norway and Sweden, where ACVs for the primary 
series were introduced in 1996 and 1998, respectively, 
which is earlier than in the UK (in 2000), Finland and 
the Netherlands (both in 2005) (Table 1). Notably, in 
France an ACV booster was introduced in 1998, while 
the WCV for the primary series was replaced with an 
ACV in 2004 [29]. The timing of these changes is similar 
to that in Norway which, as in France, has a relatively 
high percentage of Prn-deficient strains. In Denmark, 
an ACV was introduced relatively early in 1997, while 
Prn-deficient strains were not detected. Unlike the vac-
cine in the other five countries in this study, which use 
ACVs containing Prn (Table 1), the Danish ACV contains 
Ptx only. As the Danish vaccine does not induce Prn 
antibodies, it is conceivable that Prn-deficient strains 
will not emerge in Denmark, if Prn-deficiency does 
not contribute to strain fitness, although overflow of 
Prn-deficient strains from neighbouring countries is 
possible.
In 2007–09, five of the 20 Norwegian strains were Prn-
deficient. Although the number of isolates tested was 
Figure 1
Immunoblot to co nfirm absence of pertactin (69 kD) 
expression in Bordetella pertussis isolates in six European 
countries, 1996–2012
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The result of isolate B3545 (fourth lane) is shown here as an 
example. A Kaleidoscope marker (161-0375, Bio-Rad, Hercules, 
US) was loaded in the  first lane. B1686 is an isogenic pertactin 
knock-out strain, which was used as a negative control. A 
commonly used reference strain, B1917, was used as a positive 
control.
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Table 4
Pertactin-deficient Bordetella pertussis isolates analysed from four European countries, 2004–12 (n=15)
Isolate name Patient’s age
Patient’s 
country of 
residence
Patient’s 
vaccination 
status
Year isolate 
recovered Sequence type
a Mutationb
B3771c 2 years Finland Vaccinated 2004 ST19 ¤6: prn2 (32_80∆[49])
B3645 7 months Norway Unknown 2007 ST13 ¤12: prn2 (1273STOP:C>T)
B3652 14 years Norway Unknown 2008 ST13 ¤12: prn2 (1273STOP:C>T)
B3654 14 years Norway Unknown 2008 ST13 ¤12: prn2 (1273STOP:C>T)
B3545 Unknown Sweden Unknown 2008 ST17 prn2 (PCRregion2::1kb)
B3657 2 months Norway Unknown 2009 ST13 ¤12: prn2 (1273STOP:C>T))
B3658 3 months Norway Unknown 2009 ST13 ¤12: prn2 (1273STOP:C>T)
B3594 1 month Sweden Unknown 2009 ST14 ¤1: prn2(-20892_-75<>[22kb])
B3582 0 months Sweden Unknown 2009 ST17 ¤4: prn2 (1613^1614::IS481[1049])
B3748 11 months Sweden Unknown 2009 ST17 prn2 (PCRregion2::1kb)
B3640 13 years Netherlands Unknown 2010 ST14 ¤4: prn2 (1613^1614::IS481[1049])
B3865 Unknown Netherlands Unknown 2011 ST14 prn2 (PCRregion2::1kb)
B3876 2 years Netherlands Unknown 2011 NI ¤10: prn2(223STOP:C>T)
B3891 Unknown Sweden Unknown 2011 NI ¤4: prn2 (1613^1614::IS481[1049])
B3977 69 years Netherlands Unknown 2012 NI ¤1: prn2(-20892_-75<>[22kb])
NI: not included in the SNP analysis; SNP: single nucleotide polymorphism; ¤: mutation number.
a Sequence type as presented in Figure 2A.
b Mutation causing the non-expression of pertactin. Numbers correspond to those in Table 5 and Figure 2A.
c This isolate was not included in the frequency analysis, because it was a single analysed Finnish strain that was isolated before 2007, but 
was included in SNP analysis and prn mutation analysis.
Figure 2
Mutations in prn2 causing non-expression of pertactin in Bordetella pertussis isolates in six European countries, 1996–2012
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prn2 (223STOP:C>T)
prn2
¤8
B.
MNMSLSRIVK  AAPLRRTTLA  MALGALGAAP  AAHADWNNQS  IVKTGERQHG
· . . . . . . . . .    
prn2
----------     -------     APP RRRMPTGTTS PSSRVVSASMprn2 (32_80∆[49])¤6:
11
::IS481
::IS481
¤5
ST
O
P
¤10
¤1
ST
O
P
¤11
¤10:
A. prn2 is shown with the surrounding genes. The arrowheads indicate the transcription direction. The variable regions 1 (R1) and 2 (R2) of 
prn are indicated in red. Numbers 1 to 13 refer to mutations (¤) in prn2 and correspond to the numbers in Table 5.
B. Detailed representation of mutation ¤6, a deletion of 49 bases in the signal sequence: prn2 (32_80‑[49]): • identical bases/amino acids, ‑ 
deleted bases/amino acids.
C. Detailed representation of mutation ¤10: a SNP leading to a stop codon: prn2 (223STOP:C>T). Base and amino acid numbering is relative to 
the prn2 initiation codon.
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low, this proportion is relatively high compared with the 
overall mean of the six countries in this period (3.4%, 
14/414). This implies that in Europe, besides France, 
Norway may also have elevated levels of Prn-deficient 
isolates. Comparisons of frequencies of Prn-deficient 
isolates should, however, be made with caution, as dif-
ferences in the period investigated, vaccination poli-
cies and isolate collection are among the factors that 
can influence the outcome. It seems valid, though, to 
conclude that the fraction of Prn-deficient strains in 
several countries of Europe is relatively low, with the 
exception of France [19] and Norway, as stated above. 
In order to confirm these findings, further studies are 
required that include more isolates for each country. 
The analyses of larger amounts of Prn-deficient strains 
may also reveal if these strains are found in higher 
frequencies in particular age groups. Future studies 
should include more southern European countries.
Mutations that were previously found to inactivate 
the prn gene [17,19,21] were also observed in the Prn-
deficient isolates analysed in this study. We found 
that the mutations in prn occurred several times inde-
pendently in different lineages, which is an indication 
that it has been fixed in the population by positive 
selection. The European Prn-deficient isolates seem to 
have originated from distinct lineages, but within the 
diverse nature of the mutations causing non-expres-
sion, we also observed possible signs of clonal expan-
sion of a Prn-deficient strain in Norway. Notably, the 
specific point mutation that occurred in five Norwegian 
isolates was also found in seven of 12 Prn-deficient 
isolates collected in Philadelphia in the US [21]. It was 
previously suggested that the spread of Prn-deficient 
isolates in Japan was the result of clonal expansion 
[18].
The production of bacterial virulence factors, such as 
pertactin, involves ‘costs and benefits’ for the bac-
teria. Costs include the energy used to express the 
virulence factors and activation of the host immune 
response against these antigens. Benefits comprise 
attachment to host tissues and manipulation of host 
defences. We hypothesise that the switch from WCV 
to ACV has affected the balance between these costs 
and benefits of Prn production to the extent that 
strains that do not produce Prn are able to expand. In 
support of this, our phylogenetic analysis indicates 
Prn-deficiency is subject to positive selection. We 
postulate that, because non-expression of one of the 
Table 5
Mutations in the pertactin gene causing loss of pertactin expression
Number of the 
mutationa Name of the mutation
b Note Reference
¤1 prn2 (-20892_-75<>[22Kb]) Inversion of about 22 kb in the promoter [21, this work]
¤2 prn2 (-1846_553∆[2399]) Deletion of the first part of prn2 and upstream BP1053 [16]
¤3 prn2 (245^246::IS481[1049]) Insertion of IS481 in prn2, between position 245 and 246 [20]
¤4 prn2 (1613^1614::IS481[1049]) Insertion of IS481 in prn2, between position 1,613 and 1,614 [16, this work]
¤5 prn2 (2735^2736::IS481[1049]) Insertion of IS481 in prn2, between position 2,735 and 2,736 [21]
¤6 prn2 (32_80∆[49]) Deletion in prn2 signal sequence [this work]
¤7 prn2 (∆prn) Deletion of the entire prn gene [18]
¤8 prn2 (1043_1067∆[25]) 25 bp deletion in first repeat region [18]
¤9 prn2 (∆[89]) 89 bp deletion at 5' of prn [18]
¤10 prn2 (223STOP:C>T) SNP C>T, leading to a stop codon [this work]
¤11 prn2 (760STOP:C>T) SNP C>T, leading to a stop codon [21]
¤12 prn2 (1273STOP:C>T) SNP C>T, leading to a stop codon [20, this work]
¤13 prn2 (1479STOP) SNP leading to a stop codon [18]
¤14 prn1 (1598^1599::IS481[1049]) Insertion of IS481 in prn1, also found in reverse direction [17] 
¤15 prn1 ∆SS Deletion in prn1 signal sequence [17,19,21]
bp: base pairs; IS: insertion element; kb: kilobase pairs; SNP: single nucleotide polymorphism; ¤: mutation number.
a  As presented in Figure 2, except for ¤14 and ¤ 15.
b  The name is composed as follows: pertactin gene (prn) allele (position from open reading frame of the prn gene/type of mutation/[size of 
the mutation]). 
x_y  from position x to y
x^y  between position x and y
 <>  inversion  
::IS481   insertion of IS481
∆    deletion
STOP:C>T   SNP (C to T) leading to a premature stop codon
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Figure 3
Characterisation of the prn gene from pertactin-deficient Bordetella pertussis isolates by polymerase chain reaction, from six 
European countries, 1996–2012
PCR 1
PCR 2
PCR 3
PCR 4
A.
B.
4000
3000
2000
1000
750
500
250
 PCR1 PCR2 PCR3 PCR4 
Marker   ¤ or ¤5 ¤6  ¤4 not 
¤3  ¤6  ¤6 
 WT :: [~1kb] ∆[~100bp] WT :: [~1kb] WT ∆[~100bp] WT ∆[~100bp] 
         
C.
3,¤4
¤5or 
ST
O
P
¤6¤2
R1 R2
ST
O
P
prn2upp cysGBP1053
::IS481
::IS481
¤4
¤12 ¤13
::IS481
¤3
¤8
::IS481
::IS481
¤5
ST
O
P
¤10
¤1
ST
O
P
¤11
¤ 10-13 ¤ 10-13 ¤ 10-13 ¤ 10-13
bp: base pairs; kb: kilobase pair; PCR: polymerase chain reaction; WT: wild type.
A. The prn gene and surrounding genes.
B. The grey bars represent the regions targeted in the PCR that were used to identify insertion and deletion mutations in prn. For the primers, 
see Table 3.
C. The PCR products of the WT prn allele were compared with PCR products derived from Prn-deficient strains. PCR fragments were sized by 
capillary electrophoresis. On the basis of the primers used and the size of the PCR fragments, the type of mutation was derived, as shown 
above the lanes. Designation of PCR fragments as in (B) and mutations as in Table 5. The first lane contains the size marker DNA (in bp). 
PCR2 distinguishes ¤4 from ¤3 or ¤5, which does not result from PCR1. Mutations 10–13 yielded WT products for the PCRs.
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vaccine antigens contributes relatively little to immune 
evasion of a broad immune response, vaccination with 
WCVs limits the advantage of Prn-deficient isolates. 
Conversely, if the immune response is directed against 
a limited number of antigens (one to five in the case of 
ACVs), non-expression of one of the vaccine antigens 
may confer a considerable selective advantage. This 
is especially the case when high antibody titres are 
induced, as is observed for ACVs [38]. However, further 
studies are required to substantiate this hypothesis.
The emergence of Prn-deficient strains raises ques-
tions about its role in pertussis. An analysis of clini-
cal symptoms caused by Prn-positive and Prn-negative 
isolates in infants did not reveal major differences 
between the two groups, which suggests that lack of 
Prn in B. pertussis does not affect virulence in infants 
substantially [29]. Other important questions that 
should be addressed in the future are the effect, if 
any, of Prn-deficiency on the efficacy of pertussis vac-
cines and whether Prn-deficient strains prevail more in 
groups with a particular level of immunity. This study 
establishes a baseline for investigations into the emer-
gence and spread of Prn-deficient strains in Europe. 
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